Orchid Pharma Limited has announced that a meeting of its Board of Directors is scheduled for Monday, May 25, 2026. The primary agenda is to review and approve the company’s standalone and consolidated audited financial results for the quarter and financial year ended March 31, 2026. In accordance with internal compliance protocols, the company’s trading window remains closed for all designated persons until 48 hours after the results are declared.
Board Meeting Agenda
The Board of Directors of Orchid Pharma Limited will convene on May 25, 2026, to evaluate the company’s performance for the fourth quarter and the full financial year 2025-26. The session will focus on the finalization of the standalone and consolidated audited financial statements, providing stakeholders with an overview of the company’s fiscal health for the period ending March 31, 2026.
Trading Window Update
In preparation for the upcoming financial disclosure, Orchid Pharma has confirmed that the trading window for its securities has been closed since April 01, 2026. This restriction is standard practice to ensure confidentiality and market fairness. The window will remain inaccessible to designated employees and insiders until 48 hours have elapsed following the public release of the audited financial results.
Source: BSE
